Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study.
about
Treatment of Helicobacter pylori infection: Current and future insightsHelicobacter pylori: Effect of coexisting diseases and update on treatment regimensCurrent Helicobacter pylori treatment in 2014Meta-analysis: is combination of tetracycline and amoxicillin suitable for Helicobacter pylori infection?Does emerging Clarithromycin resistance signal an obituary to empirical standard triple therapy for Helicobacter pylori infection?Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance.Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: an Asian perspective.Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.Comparison of three different regimens against Helicobacter pylori as a first-line treatment: A randomized clinical trialRational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidenceBismuth-containing quadruple therapy for Helicobacter pylori: lessons from ChinaChoosing optimal first-line Helicobacter pylori therapy: a view from a region with high rates of antibiotic resistance.Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial.Treatment of Helicobacter pylori infection 2013.Evidence-based recommendations for successful Helicobacter pylori treatment.Helicobacter pylori: future perspectives in therapy reflecting three decades of experience.Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance.Treatment of Helicobacter pylori infection 2014.Review: clinical management of Helicobacter pylori infection in China.How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly.Furazolidone, an Underutilized Drug for H. pylori Eradication: Lessons from Iran.Tyrosyl-tRNA synthetase inhibitors: a patent review.Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies.Efficacy of three-in-one capsule bismuth quadruple therapy for Helicobacter pylori eradication in clinical practice in a multinational patient population.H. pylori Management in ASEAN: the Bangkok Consensus Report.Tetracycline- and furazolidone-containing quadruple regimen as rescue treatment for Helicobacter pylori infection: a single center retrospective study.Hp-normogram (normo-graham) for Assessing the Outcome of H. pylori Therapy: Effect of Resistance, Duration, and CYP2C19 Genotype.Inefficacy of triple therapy and comparison of two different bismuth-containing quadruple regimens as a firstline treatment option for helicobacter pylori.Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy.Rifabutin Containing Triple Therapy and Rifabutin with Bismuth Containing Quadruple Therapy for Third-Line Treatment of Helicobacter pylori Infection: Two Pilot Studies.Colloidal bismuth subcitrate impedes proton entry into Helicobacter pylori and increases the efficacy of growth-dependent antibiotics.Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial.Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments.Optimized high-dose amoxicillin-proton-pump inhibitor dual therapies fail to achieve high cure rates in China.RE: Effects of helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups.Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial.Human Lysozyme Synergistically Enhances Bactericidal Dynamics and Lowers the Resistant Mutant Prevention Concentration for Metronidazole to Helicobacter pylori by Increasing Cell Permeability.Therapeutic Endoscopy in Combination with Quadruple Therapy in Treating Bleeding Caused by Gastric Ulcer.Efficacy and Tolerability of Two Quadruple Regimens: Bismuth, Omeprazole, Metronidazole with Amoxicillin or Tetracycline as First-Line Treatment for Eradication of Helicobacter Pylori in Patients with Duodenal Ulcer: A Randomized Clinical Trial.Outcomes of furazolidone- and amoxicillin-based quadruple therapy for infection and predictors of failed eradication
P2860
Q26769707-37180800-71BF-4E5B-84F1-29BE2EFBAE84Q26777635-D766FA66-47CC-4C9A-B293-F7980321B684Q27000209-558C560C-6179-4D60-9C5B-C06B3E343D50Q28082104-B28C900B-554E-49B7-89DF-290D17230EF7Q30381104-B17589CD-3A3C-45B6-BE32-F938A7073C09Q33639114-BB7FB04C-04F8-4EAB-A728-E1C418DC6598Q35598058-302824BA-6997-4579-81EF-11A021CFCC32Q36086358-3F3E82EE-77C6-497E-82D6-9567E8B5249BQ36614237-D7AEA71B-9F5E-4CAC-AEC7-C0BD81DDE077Q37315773-9EF262B1-895F-4290-8C6F-FCD013A6DB15Q37397744-9A0F917E-4CF1-4D5F-B9B7-EB8310E56881Q37649367-3CFC0407-4420-41B9-80A5-2B55E06B42BDQ37656247-390622D5-C99B-4E91-8C39-46B09C698EB5Q38134877-70785592-E491-4EA8-ABC8-775E894364ABQ38177322-27012D40-9CCB-425B-B4CC-2B185D0132F8Q38191566-A0118BF7-848F-4A15-A0D1-78B207E7059BQ38238745-22FFE2EC-E7B3-4F38-8FD9-D179910135F3Q38244257-474EF944-59A4-43C4-9DBD-983E689714CFQ38266432-76EAE2B9-4A41-47E2-B30C-53B5CB92E01FQ38575216-C4A99992-0C42-4E0D-9D1B-31DCCE229DBBQ38747268-FCF5B4A1-F06D-4914-BB84-72091CD72F2CQ39039062-A5E1BDAA-C613-4C53-9F07-ABDD2D8A9E3FQ39278632-6A4D64E3-B446-4639-8BAD-7E99C90171D7Q40082686-1EAE784F-BB45-4A23-923C-0A148B619E50Q40100019-CA995588-6E99-4841-A748-A00369C1C756Q40206483-B04379E8-8B38-4B2B-AADE-8842B29F7AA3Q40268942-57F4A78A-8188-44B6-8755-5811DE44FB18Q40504369-F98DE371-C54E-494B-89E4-894C80E4AD1AQ40526981-0D87EAD0-CFBF-4183-A9A9-5932A2D1D102Q40819420-95FD943F-2FF6-4FB3-85EC-B35072CEF16EQ41074387-E5149F11-B78F-4E1D-BAA1-00148970E875Q41326393-03D2FBE0-096B-4DB1-A7CA-81A3E0110727Q41471323-CE057BC1-9645-412E-A73C-0A25653B001EQ41867496-2F5A9578-8330-4E25-B0CF-EE5A1841AE89Q43155529-6C54A1E8-0F79-4A39-B013-E367D53588CAQ45895252-72F202C4-7337-4600-BBE9-C91ACFC4CA55Q48948199-4EDFE999-06D5-4F4C-9331-EA98113E9763Q55076938-13642C4A-C938-44D0-9988-53FC1FE44CB3Q55280909-9EED7384-E5EF-49CD-8418-7552D7C7912EQ58602131-697A87DB-08A6-4AF5-9040-187486CADB4A
P2860
Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Efficacy of bismuth-containing ...... ctions in a prospective study.
@en
Efficacy of bismuth-containing ...... ctions in a prospective study.
@nl
type
label
Efficacy of bismuth-containing ...... ctions in a prospective study.
@en
Efficacy of bismuth-containing ...... ctions in a prospective study.
@nl
prefLabel
Efficacy of bismuth-containing ...... ctions in a prospective study.
@en
Efficacy of bismuth-containing ...... ctions in a prospective study.
@nl
P2093
P1476
Efficacy of bismuth-containing ...... ctions in a prospective study.
@en
P2093
Qing Zheng
Qinjuan Sun
Shudong Xiao
Wenzhong Liu
Xiao Liang
Xiaoqing Xu
P304
P356
10.1016/J.CGH.2013.01.008
P407
P577
2013-01-29T00:00:00Z